Back to News
Market Impact: 0.4
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
Source: PR Newswire
M&A & RestructuringHealthcare & BiotechProduct Launches
PTC Therapeutics completed its previously announced acquisition of Sangamo Therapeutics' ST-920, a BLA-stage, one-time therapy candidate. Completion of the biologics license application submission is expected in Q4 2026, adding a late-stage asset to PTC's rare-disease pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
PTCT0.65
SGMOQ0.45
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- RIP the Cybertruck: Elon Musk says Tesla will wind down production of its most polarizing EV
- Tesla will stop making the Cybertruck in 2027
- Goldman Sachs raises Unity Software stock price target on strong Q3 results
- Globus Medical stock holds at Neutral as BTIG cites revenue miss
- Needham reiterates Buy on Five9 stock after strong AI growth